Published in Cancer Res on May 01, 2008
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 8.88
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Asymmetric cell division: recent developments and their implications for tumour biology. Nat Rev Mol Cell Biol (2010) 3.28
Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev (2009) 2.99
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell (2011) 2.87
Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell (2012) 2.85
Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer. Genes Dev (2009) 2.76
Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell (2014) 2.14
Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell (2009) 2.12
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J (2009) 1.66
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Sociability and motor functions in Shank1 mutant mice. Brain Res (2010) 1.60
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells (2013) 1.49
Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes. Cancer Cell (2015) 1.49
Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc Natl Acad Sci U S A (2011) 1.41
The pathobiology of glioma tumors. Annu Rev Pathol (2010) 1.40
Molecular pathogenesis of bladder cancer. Int J Clin Oncol (2008) 1.33
The interface between glial progenitors and gliomas. Acta Neuropathol (2008) 1.33
Inducible site-specific recombination in neural stem/progenitor cells. Genesis (2009) 1.31
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci (2011) 1.28
Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol (2013) 1.26
Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int (2012) 1.23
Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics (2009) 1.22
MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol (2013) 1.20
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res (2013) 1.15
FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res (2010) 1.14
STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med (2009) 1.13
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev (2010) 1.11
Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther (2009) 1.10
GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma. Mol Cancer Res (2009) 1.09
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther (2013) 1.07
Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep (2011) 1.04
ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. Oncogene (2012) 1.04
The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Front Oncol (2012) 1.01
Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. Clin Cancer Res (2009) 1.00
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res (2014) 1.00
Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res (2013) 0.99
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer (2012) 0.99
The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol (2014) 0.96
Measuring brain tumor growth: combined bioluminescence imaging-magnetic resonance imaging strategy. Mol Imaging (2009) 0.94
Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. Biochim Biophys Acta (2013) 0.93
Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med (2009) 0.93
Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev (2011) 0.92
On the origin of glioma. Ups J Med Sci (2012) 0.92
ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro. Neuro Oncol (2013) 0.91
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. J Natl Cancer Inst (2015) 0.90
Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci (2012) 0.89
Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med (2010) 0.88
What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A (2010) 0.88
Brain stem cells as the cell of origin in glioma. World J Stem Cells (2014) 0.88
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Oncogene (2013) 0.87
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. PLoS One (2012) 0.87
The bright and the dark sides of DNA repair in stem cells. J Biomed Biotechnol (2010) 0.87
Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. Stem Cells (2014) 0.86
Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling. Development (2015) 0.86
Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. J Oncol (2010) 0.86
Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro Oncol (2014) 0.86
Immunoexcitatory mechanisms in glioma proliferation, invasion and occasional metastasis. Surg Neurol Int (2013) 0.84
Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma. Sci Rep (2016) 0.84
Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. Bone (2011) 0.83
The impact of coexisting genetic mutations on murine optic glioma biology. Neuro Oncol (2014) 0.81
What underlies the diversity of brain tumors? Cancer Metastasis Rev (2013) 0.81
Generation of cancerous neural stem cells forming glial tumor by oncogenic stimulation. Stem Cell Rev (2012) 0.80
Review: insights gained from modelling high-grade glioma in the mouse. Neuropathol Appl Neurobiol (2012) 0.80
Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget (2012) 0.80
In vivo optical imaging of brain tumors and arthritis using fluorescent SapC-DOPS nanovesicles. J Vis Exp (2014) 0.80
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. Dis Model Mech (2014) 0.80
Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. J Biomed Biotechnol (2009) 0.79
Mice lacking neurofibromin develop gastric hyperplasia. Am J Physiol Gastrointest Liver Physiol (2009) 0.79
Nitroxoline induces apoptosis and slows glioma growth in vivo. Neuro Oncol (2014) 0.79
Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. Cancer Res (2016) 0.78
Glial progenitors as targets for transformation in glioma. Adv Cancer Res (2014) 0.78
PTEN degradation after ischemic stroke: a double-edged sword. Neuroscience (2014) 0.77
Improved Adeno-associated Viral Gene Transfer to Murine Glioma. J Genet Syndr Gene Ther (2013) 0.77
In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cell Mol Life Sci (2014) 0.76
Modeling cytomegalovirus infection in mouse tumor models. Front Oncol (2015) 0.76
An in silico screen links gene expression signatures to drug response in glioblastoma stem cells. Pharmacogenomics J (2014) 0.76
Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathol (2016) 0.76
Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery. Curr Protoc Pharmacol (2016) 0.75
The E3 ubiquitin ligase CHIP/miR-92b/PTEN regulatory network contributes to tumorigenesis of glioblastoma. Am J Cancer Res (2017) 0.75
Mechanisms of increased risk of tumorigenesis in Atm and Brca1 double heterozygosity. Radiat Oncol (2011) 0.75
Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC Med (2016) 0.75
When flies and mice develop cancer. Meeting on development and cancer. EMBO Rep (2008) 0.75
Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. Neurotherapeutics (2017) 0.75
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol (2016) 0.75
CNS Tumors in Neurofibromatosis. J Clin Oncol (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
Tumor spectrum analysis in p53-mutant mice. Curr Biol (1994) 16.60
Mammalian neural stem cells. Science (2000) 16.09
Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell (1999) 15.87
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 13.98
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 10.56
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 6.84
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol (1998) 6.38
hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis (2001) 6.29
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16
Pten regulates neuronal arborization and social interaction in mice. Neuron (2006) 6.11
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia (2002) 5.81
Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell (2002) 5.64
Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons. Neuron (1999) 5.59
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet (2000) 5.28
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci (2006) 4.90
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet (2000) 3.98
A unified hypothesis on the lineage of neural stem cells. Nat Rev Neurosci (2001) 3.86
Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst (1999) 3.41
Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res (2004) 2.75
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
The molecular and genetic basis of neurological tumours. Nat Rev Cancer (2002) 2.41
Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science (1997) 2.30
TrkB has a cell-autonomous role in the establishment of hippocampal Schaffer collateral synapses. J Neurosci (2005) 2.21
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res (2006) 1.80
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res (2001) 1.53
Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell (2002) 1.48
Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res (2005) 1.47
Neuron-specific enolase-cre mouse line with cre activity in specific neuronal populations. Genesis (2006) 1.43
High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res (2006) 1.42
Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res (2006) 1.37
Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest (1998) 1.26
Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res (2005) 1.24
Differential expression of Rho family GTP-binding proteins and protein kinase C isozymes during C6 glial cell differentiation. Brain Res Mol Brain Res (1997) 0.90
Timing of p53 mutations during astrocytoma tumorigenesis. Hum Mol Genet (1993) 0.83
Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med (2013) 24.88
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 8.88
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 7.35
Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med (2015) 6.68
Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2007) 6.67
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Pten regulates neuronal arborization and social interaction in mice. Neuron (2006) 6.11
Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J (2003) 5.78
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science (2002) 5.08
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg (2010) 4.75
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41
Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet (2007) 4.09
TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron (2008) 4.00
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell (2011) 3.56
SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev (2002) 3.49
Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell (2010) 3.41
Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A (2004) 3.40
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science (2006) 3.26
A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell (2012) 3.26
The divergent Robo family protein rig-1/Robo3 is a negative regulator of slit responsiveness required for midline crossing by commissural axons. Cell (2004) 3.19
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15
In situ proteolysis for protein crystallization and structure determination. Nat Methods (2007) 3.05
High-performance thin-film transistors using semiconductor nanowires and nanoribbons. Nature (2003) 3.01
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem (2003) 2.91
Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci (2009) 2.90
Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc Natl Acad Sci U S A (2009) 2.88
Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell (2012) 2.85
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
Essential and overlapping functions for mammalian Argonautes in microRNA silencing. Genes Dev (2009) 2.73
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Why mothers stop breastfeeding: mothers' self-reported reasons for stopping during the first year. Pediatrics (2008) 2.68
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell (2008) 2.65
Nf1 has an essential role in endothelial cells. Nat Genet (2002) 2.63
Molecular imaging of hypoxia. J Nucl Med (2008) 2.61
ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab (2006) 2.55
Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell (2012) 2.54
PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol (2004) 2.52
Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res (2009) 2.49
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature (2008) 2.47
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Novel reassortant highly pathogenic H5N2 avian influenza viruses in poultry in China. PLoS One (2012) 2.43
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development (2002) 2.42
The molecular and genetic basis of neurological tumours. Nat Rev Cancer (2002) 2.41
Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39
Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron (2004) 2.38
Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry (2006) 2.36
Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. Stroke (2008) 2.32
PTENless means more. Dev Biol (2004) 2.31
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency. Mol Cell Biol (2005) 2.30
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Rabies encephalomyelitis: clinical, neuroradiological, and pathological findings in 4 transplant recipients. Arch Neurol (2005) 2.29
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
TrkB has a cell-autonomous role in the establishment of hippocampal Schaffer collateral synapses. J Neurosci (2005) 2.21
Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia (2010) 2.21
High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J Surg Oncol (2006) 2.19
Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. J Neurosci (2002) 2.16
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell (2009) 2.14
Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell (2009) 2.12
The insulin-regulated CREB coactivator TORC promotes stress resistance in Drosophila. Cell Metab (2008) 2.09
Upregulation of a T-type Ca2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus. J Neurosci (2002) 2.09
Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem (2008) 2.07
PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A (2009) 2.07
Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol (2003) 2.05